A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters

• Status: Terminated
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UCB Biopharma S.P.R.L.; Upsher-Smith Laboratories
• Treatments: Midazolam

Criteria

Inclusion Criteria:

1. Has a competent, adult caregiver(s) who is able to recognize and observe the subject's seizure cluster episodes

2. Has an established diagnosis of partial or generalized epilepsy that includes all the following:

• A documented history of seizure clusters lasting a minimum of 10 minutes, seizure cluster pattern is observable, stereotyped, and recognizably different from the subject's other non-cluster seizure activity (if any)

• A second seizure in the seizure cluster typically occurs within 6 hours from the time of recognition

• A seizure cluster pattern composed of multiple (≥ 2) partial or generalized seizures

• A seizure cluster pattern established >3 months before Visit 1

• A frequency of ≥ 3 stereotyped seizure clusters during the year before Visit 1

• At least 1 stereotyped seizure cluster occuring ≤ 4 months before Visit 1

3. Currently on a stable regimen of AED(s) that includes a benzodiazepine

4. Weight is 40 kg to 125 kg, inclusive

Exclusion Criteria:

1. Has a neurological disorder that is likely to progress in the next year

2. Has a severe chronic cardio-respiratory disease

3. Has a psychogenic, non-epileptic seizure(s) within the 5 years before Visit 1

4. Has a history of their stereotypical seizure cluster progressing to status epilepticus within 2 years before Visit 1

5. Has a history of acute narrow-angle glaucoma

6. Has had active suicidal plan/intent or active suicidal thoughts in the 6 months before Visit 1 or a suicide attempt in the past 5 years